Table 5.

Reasons for not receiving GDT (n = 106)

Reason	Frequency (%)
No actionable mutations	11 (10%)
Disease in remission/no indication for therapy	18 (17%)
Patient still receiving standard of care/off-label option or clinical trial not suggested by F1 report	42 (40%)
Patient is no longer a candidate for therapy due to deteriorating or poor performance status	25 (23%)
Physician preference for no GDT specifically because of rapid disease	5 (5%)
On/off label GDT recommended or clinical trial available locally but patient declined	3 (3%)
Patient offered clinical trial but unable to travel/insurance decline	2 (2%)